A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2011 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 20 Jan 2011 Planned end date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.